ALOS3:BMFBOVESPAAllos S.A. Analysis
Data as of 2026-05-28 - not real-time
R$28.55
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Allos S.A. (ALOS3) is trading at R$28.55, roughly 8% above its discounted cash‑flow fair value of R$26.24. The stock’s PE ratio of 17.2 sits well below the industry average of 32.7, suggesting relative valuation cheapness. However, the dividend yield of 9.3% is backed by a payout ratio of 143%, raising concerns about sustainability. The balance sheet is heavily leveraged, with a debt‑to‑equity of 47.6 and net cash of only R$24.9 million against R$6.2 billion of debt. Technicals show a bearish MACD, a RSI of 40, and decreasing volume, placing the price near the support level of R$27.61. Despite these pressures, analysts forecast a median target price of R$34, implying roughly 20% upside from current levels.
The company’s gross margin of 74% and operating margin of 59% indicate strong operational profitability. Cash generation is solid, with free cash flow of R$1.34 billion and operating cash flow of R$1.8 billion. The beta of 0.75 and 30‑day volatility of 26.5% signal moderate market sensitivity but elevated price swings. Real‑estate services in Brazil carry medium regulatory and geographic risk, amplified by the country’s macro‑economic volatility. Given the mix of undervalued multiples, high leverage, and dividend sustainability doubts, the stock sits at a fair valuation point. Investors should weigh the potential upside to the target price against the debt burden and dividend risk before taking a position.
The company’s gross margin of 74% and operating margin of 59% indicate strong operational profitability. Cash generation is solid, with free cash flow of R$1.34 billion and operating cash flow of R$1.8 billion. The beta of 0.75 and 30‑day volatility of 26.5% signal moderate market sensitivity but elevated price swings. Real‑estate services in Brazil carry medium regulatory and geographic risk, amplified by the country’s macro‑economic volatility. Given the mix of undervalued multiples, high leverage, and dividend sustainability doubts, the stock sits at a fair valuation point. Investors should weigh the potential upside to the target price against the debt burden and dividend risk before taking a position.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish MACD and decreasing volume
- Price near support at R$27.61
- Unsustainable dividend payout
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- PE well below industry average
- Target price offers ~20% upside
- Strong operating margins and cash flow
Long Term
> 3 yearsNeutral
Model confidence: 7/10
Key Factors
- High debt‑to‑equity ratio
- Dividend sustainability concerns
- Stable sector fundamentals
Key Metrics & Analysis
Financial Health
Revenue Growth2.10%
Profit Margin28.04%
P/E Ratio17.2
ROE6.86%
ROA3.77%
Debt/Equity47.65
P/B Ratio1.1
Op. Cash FlowR$1.8B
Free Cash FlowR$1.3B
Industry P/E32.7
Technical Analysis
TrendNeutral
RSI40.2
SupportR$27.61
ResistanceR$31.32
MA 20R$29.33
MA 50R$30.41
MA 200R$27.98
MACDBearish
VolumeDecreasing
Fear & Greed Index91.54
Valuation
Fair ValueR$26.24
Target PriceR$35.04
Upside/Downside22.73%
GradeFair
TypeValue
Dividend Yield9.32%
Risk Assessment
Beta0.75
Volatility26.48%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.